GenePORTER® Gold from Amsbio is a highly reproducible, lipid-based gene transfection reagent delivering exceptional efficiency across the widest range of cell lines. Utilizing proprietary Advanced Carrier Enhancement (ACE) technology - GenePORTER® Gold delivers outstanding transfection efficiency and transgene expression levels with minimal cytotoxicity.
The transfection efficiency levels achieved with GenePORTER Gold match or surpass other commercially available transfection reagents. The GenePORTER Gold kit includes an easy-to-use protocol and enough reagent for 400 x 1 microgram…
Amsbio offers a wide range of highly pure, lyophilized exosome standards designed to support reproducibility and standardization in extracellular vesicle (EV) research.Exosomes are small lipid nanoparticles actively secreted by exocytosis in most living cells. Regulating pleiotropic physiological and pathological functions – exosomes have been shown to play significant roles in diverse pathological conditions such as cancer, infectious and neurodegenerative diseases. Currently there is growing interest in exosomes as promising new tools for use such as biomarkers and therapeutics.The…
Two groundbreaking drug discovery projects, supported by Medicines Discovery Catapult (MDC), have secured over £1m in funding from Innovate UK's Launchpad Northern Ireland programme.
SignaCor Therapeutics and Klas Therapeutics, both based in Northern Ireland, have been awarded a share of funding from the Launchpad programme.
The funding provides a vital boost to the SMEs' research programmes, which focus on innovations to treat heart disease and skin cancer.
MDC, a national Life Science service dedicated to supporting drug discovery teams to develop marketed therapies, will…
Engineered and humanized antibodies are now taking charge of the driving force behind a new era in drug discovery, from breakthrough cancer treatments to next-gen biologics.The Antibody Revolution: Precision Weapons Against CancerAs highlighted in industry main news channels Trends in Biotechnology and SciTechDaily, recombinant antibodies—customized for enhanced potency and accuracy—are making tidal waves in the immunotherapy space. But while demand skyrockets, high-quality antibody reagents remain notoriously hard to come by.Creative Biolabs, enthusiastically coming in to AI-driven antibody…
LONDON, UK, and MELBOURNE, Australia, July 15, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for QBiotics Group Limited (QBiotics) and is pleased to announce the placement of Sergio Duchini as Non-executive Director.QBiotics is an unlisted public Australian life sciences company that specializes in the discovery and development of novel small molecules to treat complex medical conditions. Its current therapeutic focus is on oncology and wound healing. The…
Internationally recognised leaders will provide expert technical guidance to support Arecor in its mission to develop a game-changing oral delivery of peptides technology platform
Cambridge, UK,14 July 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the formation of its new Scientific Advisory Board of internationally recognised experts in the fields of oral drug delivery and peptide therapeutics.
Arecor is leveraging its significant formulation and product development expertise to develop a…
Aubagne, France; Bratislava, Slovakia/Boston, US/Oxford, UK | July 10, 2025 New partnership to advance cell-based mRNA production Sartorius to support GMP readiness through integrated process development and facility design Expansion planned across Europe and North America Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, and Sensible Biotechnologies, a pioneer in cell-based design and manufacturing of mRNA therapeutics, have signed a Memorandum of Understanding (MoU). The two companies will jointly advance the…
Experienced Life Sciences Ecosystem Super-connector Joins the Innovative Industry Membership Organisation
Cambridge, UK: 10 July 2025
One Nucleus, the Cambridge based not-for-profit membership organisation for life science businesses, is delighted to announce the appointment of Philippa Clark as their new Director of Business Development.
Philippa is a highly experienced professional in the life sciences sector with twenty years’ experience in client development and engagement to support growth. Philippa actively participates in numerous accelerator and mentoring…
London, July 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for iOnctura and is pleased to announce the placement of Steven Sciuto as Chief Financial Officer.iOnctura is a clinical-stage precision oncology company combating neglected and hard-to-treat cancers with a pipeline of first-in-class small molecules.Steven Sciuto is a seasoned finance executive with more than 15 years of corporate finance leadership and capital markets experience within…
Read July eNews here 👉 https://shorturl.at/OHhJc
Featuring:
✅ A Sense of Togetherness to Succeed in Tough Times by Tony Jones, CEO, One Nucleus
✅ Unlocking Strategic Procurement in Life Sciences, 18 June 2025 by Alicia Gailliez, Business Development Manager, One Nucleus
✅ Will London, 3 December 2025, be the Genesis of Your Next Step to Success? by Tony Jones, One Nucleus
✅ Targeting the Right Investors at the Right Time with the Right Proposition – How One Nucleus Can Support Members on the Fundraising Trail by Tony Jones, One Nucleus
✅ Bridging the Knowledge Gap: Why Training Your Team on…